0000805928-22-000033.txt : 20220318
0000805928-22-000033.hdr.sgml : 20220318
20220318161010
ACCESSION NUMBER: 0000805928-22-000033
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220316
FILED AS OF DATE: 20220318
DATE AS OF CHANGE: 20220318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sandberg Eric
CENTRAL INDEX KEY: 0001764446
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36046
FILM NUMBER: 22752623
MAIL ADDRESS:
STREET 1: C/O AXOGEN, INC.
STREET 2: 13631 PROGRESS BLVD., SUITE 400
CITY: ALACHUA
STATE: FL
ZIP: 32615
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axogen, Inc.
CENTRAL INDEX KEY: 0000805928
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 411301878
STATE OF INCORPORATION: MN
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 13631 PROGRESS BLVD.
STREET 2: SUITE 400
CITY: ALACHUA
STATE: FL
ZIP: 32615
BUSINESS PHONE: (386) 462-6817
MAIL ADDRESS:
STREET 1: 13631 PROGRESS BLVD.
STREET 2: SUITE 400
CITY: ALACHUA
STATE: FL
ZIP: 32615
FORMER COMPANY:
FORMER CONFORMED NAME: AxoGen, Inc.
DATE OF NAME CHANGE: 20111004
FORMER COMPANY:
FORMER CONFORMED NAME: LECTEC CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
wf-form4_164763418939739.xml
FORM 4
X0306
4
2022-03-16
0
0000805928
Axogen, Inc.
AXGN
0001764446
Sandberg Eric
13631 PROGRESS BLVD
SUITE 400
ALACHUA
FL
32615
0
1
0
0
Chief Commercial Officer
Common Stock
2022-03-16
4
M
0
6000
0
A
14310
D
Common Stock
2022-03-16
4
F
0
1512
7.97
D
12798
D
Restricted Stock Units
2022-03-16
4
M
0
6000
0
D
Common Stock
6000.0
6000
D
Restricted Stock Units
2022-03-16
4
A
0
62910
0
A
Common Stock
62910.0
62910
D
Employee Stock Option (right to purchase)
10.25
2022-03-16
4
A
0
60576
0
A
2032-03-16
Common Stock
60576.0
60576
D
This reflects the number of restricted stock units that became vested as of March 16, 2022.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.
All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.
/s/ Eric Sandberg
2022-03-18